If two dermal fillers both contain hyaluronic acid (HA), why can one syringe cost substantially more than another?
It is an increasingly relevant question for practitioners comparing European dermal fillers UK ranges with Korean dermal fillers UK alternatives. The short answer is that “contains HA” tells you only one part of the story. It does not tell you how the HA has been processed, how the gel behaves, how the range is segmented, what evidence supports it, or how much manufacturer infrastructure sits behind it.
This is not a European-good/Korean-bad comparison. Lower acquisition cost does not automatically mean lower quality, and a premium price does not automatically make a filler the right choice for every treatment objective.
Shop by route: Galderma Aesthetics → Restylane | Allergan Aesthetics → JUVÉDERM | Revolax | LumiFill | All Dermal Fillers
Hyaluronic acid is the starting point, not the whole product
HA fillers can differ in the source and purification of their raw material, manufacturing process, cross-linking chemistry, HA concentration, gel structure and the amount of free versus cross-linked HA. These variables influence properties such as firmness, cohesivity, flexibility, extrusion force and tissue integration.
That is why a useful hyaluronic acid fillers comparison needs to go beyond the number of milligrams of HA printed on a box.
What actually makes dermal fillers different?
Manufacturing, purification and cross-linking
Manufacturers use different proprietary processes to create a stable injectable HA gel. Cross-linking changes how quickly HA is broken down and helps create the physical properties required for an injectable implant. The finished gel therefore reflects far more than HA concentration alone.
Rheology: G′, cohesivity and flexibility
G′ is one measure of a gel’s elastic or firmness characteristics, but it should not be treated as a standalone ranking system. Cohesivity describes how strongly the gel tends to remain together, while flexibility and other rheological properties can influence how a product behaves under movement and deformation.
The important point for practitioners is not “highest G′ wins”. Different treatment objectives call for different material characteristics.
Portfolio depth and indication-led product design
A manufacturer with a broad filler portfolio can formulate different gels for different treatment objectives rather than asking one formulation to perform every role. This is one area where established premium ranges such as Restylane and JUVÉDERM have substantial portfolio depth.
Lidocaine, syringe and needle system
Where relevant, formulation with lidocaine, syringe ergonomics, plunger behaviour, extrusion force, supplied needle specifications and packaging all contribute to the practitioner experience. These are practical differences that are easy to overlook when products are compared only by cost per syringe.
Evidence, regulatory documentation and manufacturer support
Published clinical evidence varies substantially by brand and individual product. Time on market can also mean a larger body of published data and practitioner experience, although longevity alone is not evidence that one product is universally superior.
Practitioners should also consider the regulatory status and documentation for the specific product being purchased, its intended purpose, traceability, manufacturer instructions and the training or technical support available. Regulatory status should be checked product by product rather than inferred from a brand’s country of origin.
European vs Korean dermal fillers: comparison at a glance
| Factor | European / premium ranges | Korean / value ranges |
|---|---|---|
| Technology | Established proprietary gel platforms across ranges such as Restylane and JUVÉDERM | Brand-specific HA processing and cross-linking technologies; assess each manufacturer and product individually |
| Portfolio depth | Typically broad, with products differentiated for multiple treatment objectives | Varies by brand; ranges such as Revolax and LumiFill offer focused product families |
| Clinical evidence | Large established brands often have extensive product-specific published literature | Evidence base varies significantly by brand and product; review the specific product data |
| Time on market | Some leading ranges have decades of international market history | Many Korean brands are newer internationally, although market history varies |
| Regulatory status | Product-specific; verify the current UK status and documentation for the exact device | Product-specific; country of manufacture does not determine UK regulatory status |
| Rheology options | Often extensive segmentation across firmness, flexibility and treatment objectives | Varies by range; compare the physical properties of each formulation rather than origin |
| Syringe system | Proprietary syringe/needle systems and presentation vary by product | Presentation and supplied accessories vary by manufacturer and product |
| Manufacturer support | Large multinational manufacturers often provide substantial education and professional infrastructure | Support varies by manufacturer, distributor and market |
| Typical acquisition price | Generally higher across premium multinational ranges | Generally lower, creating a different clinic cost base and commercial proposition |
The table describes broad market patterns, not a safety, efficacy or regulatory ranking. Always assess the individual product and current manufacturer documentation.
Restylane: why one brand contains very different fillers
Restylane, part of the Galderma aesthetics portfolio, demonstrates why “HA filler” is too broad a category for meaningful product selection.
The Restylane family includes gels made using different Galderma technologies and designed to deliver different characteristics. NASHA technology is associated with firmer gels and structural properties, while OBT/XpresHAn technology is used across products designed with different degrees of flexibility and support. The precise formulation and intended use must be considered product by product.
That portfolio approach allows practitioners to compare products such as Restylane Kysse, Restylane Lyft, Restylane Refyne and Restylane Defyne by treatment objective and material behaviour rather than simply buying “a Restylane syringe”.
For practitioners searching Restylane vs Revolax, the most useful comparison is therefore not brand versus brand in the abstract. Compare the exact Restylane product with the exact Revolax product intended for the clinical objective.
JUVÉDERM: a differentiated family rather than one formulation
JUVÉDERM sits within the Allergan Aesthetics portfolio. Its range also illustrates how proprietary manufacturing technology creates differentiated gels within one brand family.
JUVÉDERM products use proprietary HA gel technologies across the portfolio, including HYLACROSS and VYCROSS families. Different products are formulated and positioned for different treatment objectives rather than being interchangeable simply because they share the JUVÉDERM name.
Practitioners can compare products including JUVÉDERM Ultra 2, JUVÉDERM Ultra 4, JUVÉDERM Volbella, JUVÉDERM Volift and JUVÉDERM Volux according to the relevant manufacturer information and treatment objective.
That is also the better way to approach searches such as JUVÉDERM vs Revolax: not “which brand is best?”, but which specific gel has the appropriate characteristics, documentation, evidence and cost structure for the intended use.
Revolax: a focused Korean HA filler range
Revolax is one of the Korean HA filler ranges stocked by Longeva Aesthetics. Its more accessible acquisition price is commercially significant for clinics, but price should not be used as a proxy for either quality or suitability.
The range is deliberately straightforward, with Revolax Fine, Revolax Deep and Revolax Sub-Q providing different options within the family.
For a practitioner comparing a premium European product with Revolax, look at the exact formulation, intended purpose, rheology, presentation, manufacturer documentation and available evidence—not the flag on the box.
LumiFill: another value-led Korean option
LumiFill gives practitioners another Korean HA filler buying route on Longeva Aesthetics. The live range includes LUMIFIL Lite, LUMIFIL L-Kiss and LUMIFIL L-Max.
Again, a lower acquisition price can materially change treatment economics, but the buying decision should remain product-specific. Practitioners should review the characteristics, documentation and intended use of the exact LumiFill product rather than treating “Korean filler” as one homogeneous category.
Why can premium dermal fillers cost more?
The purchase price of a syringe reflects more than the cost of its HA raw material. It can incorporate proprietary manufacturing and gel-development programmes, extensive product portfolios, clinical research, regulatory work across multiple markets, specialised delivery systems, manufacturer education and support, global commercial infrastructure and brand investment.
None of those factors automatically makes the most expensive product the best dermal filler UK choice for every patient or every indication. Equally, comparing fillers solely on acquisition price ignores meaningful differences in technology and supporting evidence.
What should practitioners compare before buying?
- The exact product—not simply the brand or country of manufacture
- Intended purpose and treatment objective
- HA concentration and formulation
- Cross-linking and gel technology
- Relevant rheological characteristics, including G′, cohesivity and flexibility
- Lidocaine content where applicable
- Syringe, needle and product presentation
- Published evidence for the specific product
- Current regulatory documentation and traceability
- Manufacturer/distributor training and support
- Acquisition price and how it fits the clinic’s treatment economics
So, is all hyaluronic acid equal?
No—not in the sense that all HA dermal filler products are equivalent. Sharing the same headline ingredient does not make two finished medical devices identical in manufacture, gel behaviour, evidence, presentation or price.
But country of origin is not a useful shortcut for deciding quality or clinical suitability either.
Don’t choose a filler simply because it is European. Don’t reject one simply because it is Korean. Compare the actual product, technology, evidence, handling characteristics and price point for the treatment objective.
Explore the four principal buying routes on Longeva Aesthetics: Galderma → Restylane, Allergan Aesthetics → JUVÉDERM, Revolax and LumiFill—or browse the complete Dermal Fillers collection.
Professional information only. Product selection and use should be based on appropriate training, the manufacturer’s current instructions and documentation, patient assessment and applicable professional requirements.